David’s reporting since 2001 has focused on the clinical aspects of medicine, particularly in the American health system. He’s covered everything from novel drugs for inflammatory bowel disease (think back to the advent of biologics!) to protocols for fine-tuning use of anticoagulants post-operatively, and from the fallout of medication compounding disasters to regulatory concerns about the 340B drug pricing program. He has covered dozens of medical conferences and profiled numerous clinicians and institutions. David is a native of Israel and lives in Toronto, Canada. His hobbies include playing music, gardening, camping and spending time with his wife, son and mini-Bernedoodle, Moishe.
Latest from David Wild
In a competitive immunology landscape, Eli Lilly is looking for novel agents, oral formulations of injectables, and combination therapies that can optimize response and expand the patient pool.
Israeli-American biotech Immunai is mapping the immune system and using AI to predict immune responses to drugs.
Novel targets for managing inflammation hold the promise of greater efficacy and safety for diseases not widely viewed as inflammatory in nature.
Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.
A new large language model by Google Research and DeepMind is the most comprehensive tool yet to potentially expedite drug development and reduce the risk of failure.
Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?